MediWound Ltd.: Business Overview, Financials & Competitive Analysis
MediWound Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical validation and market expansion potential offset near-term revenue challenges, offering asymmetric risk-reward for disciplined investors. MediWound has strong commercial validation with FDA-approved NexoBrid generating meaningful revenue, a robust Phase III pipeline asset in EscharEx targeting a large market, and significant manufacturing capacity expansion underway. However, recent quarterly revenues have.
What is MediWound Ltd.'s industry? MediWound Ltd. (mediwound.com) operates in Biopharmaceuticals - Regenerative Medicine / Wound Care. AskCyborg classifies MediWound Ltd. under Biopharmaceuticals - Regenerative Medicine / Wound Care in its company registry.
MediWound is a global biopharmaceutical company focused on enzymatic therapeutics for non-surgical tissue repair. The company's flagship FDA-approved product NexoBrid treats severe burns by selectively removing damage...
Cyborg Score thesis
Clinical validation and market expansion potential offset near-term revenue challenges, offering asymmetric risk-reward for...
Read the full analyst-debate transcript →Get the Latest MediWound Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeMediWound Ltd. Overview
Pro stress-test →MediWound is a global biopharmaceutical company focused on enzymatic therapeutics for non-surgical tissue repair. The company's flagship FDA-approved product NexoBrid treats severe burns by selectively removing damaged tissue, with EscharEx in Phase III development targeting the $2.5B chronic wound care market.
Strategic Profile
Pro stress-test →The company leverages proprietary enzymatic technology to offer safer, more effective alternatives to surgical debridement. With a cGMP-certified manufacturing facility and strategic partnerships including Vericel Corp for U.S. distribution, MediWound has treated over 16,000 patients globally and is positioned as a leader in advanced wound care innovation.
Competitive Landscape
Pro stress-test →MediWound competes in the wound debridement and burn care markets against established surgical techniques and enzymatic products like SANTYL (collagenase). The company differentiates through proprietary enzymatic technology and has published post hoc analyses showing EscharEx superiority. Key competitors include traditional surgical approaches and other wound care providers, with opportunity to capture share in the underserved chronic wounds segment.
Industry Context
MediWound Ltd. operates in Biopharmaceuticals - Regenerative Medicine / Wound Care.
Key facts
Headquarters: Yavne, Israel · Revenue: $20.9M · Market cap: $1.3B